Evaluation of the safety and effectiveness of prostate‐specific antigen (PSA) monitoring in primary care after discharge from hospital‐based follow‐up following prostate cancer treatment

Johnson, Helen; Taylor, Sally; Peat, Sara; Booker, Jane; Yorke, Janelle

doi:10.1111/ecc.13389

Cited by 3 publications

(2 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The serum biomark-ers, particularly CA 15-3 and CEA, can be very helpful in monitoring treatment response and early detection of recurrence or metastasis in breast cancer before imaging techniques show a tumor progression [45,46]. These serum biomarkers are useful for the follow-up of breast cancer patients due to their easy clinical availability, minimal invasiveness, dynamic tracking capabilities, and low cost [46,47].…”

Section: Discussionmentioning

confidence: 99%

The Influence of Tumor-Specific Markers in Breast Cancer on Other Blood Parameters

Varzaru,

Eftenoiu,

Vlad

et al. 2024

Life

View full text Add to dashboard Cite

Background: Breast cancer is the most frequently diagnosed cancer among women, responsible for the highest number of cancer-related deaths worldwide. There is limited data available related to serum tumor markers in breast cancer and other blood parameters or other glandular laboratory parameters. This study aims to evaluate the correlation of tumor-specific markers for breast cancer with other blood parameters and how these correlations could impact clinical management. Material and Method: This retrospective study represents a data analysis from 1 January 2020 to 31 May 2023, in the County Hospital of Timisoara, Romania. We reviewed all the cases where, in the laboratory analyses, the serum tumor specific biomarkers for breast cancer were analyzed. Results: A statistical analysis was performed in order to identify a possible relationship between CA 15-3 and the various biomarkers and blood parameters included in the present study. Values were classified according to reference ranges. The tests revealed no statistically significant associations between CA 15-3 values and the levels of CA125 (χ2(1) = 1.852, p = 0.174), CEA (χ2(1) = 1.139, p = 0.286), AFP (Fisher’s exact test, p = 0.341), fT4 (Fisher’s exact test, p = 0.310), TSH (Fisher’s exact test, p = 0.177), or PTH (Fisher’s exact test, p = 0.650). Conclusion: The findings indicate a lack of strong correlation between CA 15-3 and CA125, CEA, AFP, thyroid function markers, or PTH within this cohort.

show abstract

Section: Discussionmentioning

confidence: 99%

The Influence of Tumor-Specific Markers in Breast Cancer on Other Blood Parameters

Varzaru,

Eftenoiu,

Vlad

et al. 2024

Life

View full text Add to dashboard Cite

show abstract

“…Serum tumor marker (STM) has become a powerful tool for patient follow-up in many tumor species due to its advantages of easy clinical availability, dynamic monitoring, minimal invasiveness, and low cost of testing [ 5 , 6 ]. Using the follow-up modality of dynamic monitoring of STM, the elevation of STM can occur 4–6 months before imaging diagnosis of tumor metastasis, which facilitates the detection of early metastasis without clinical symptoms [ 7 – 9 ].…”

Section: Introductionmentioning

confidence: 99%

Changes of Tumor Markers in Patients with Breast Cancer during Postoperative Adjuvant Chemotherapy

et al. 2022

View full text Add to dashboard Cite

Objective. Serum tumor marker (STM) elevation can detect metastasis earlier than imaging diagnosis and, although not recommended by guidelines, is still widely used in clinical practice for postoperative follow-up of breast cancer patients. The purpose of this study was to investigate the change rules of CEA and CA153 in patients with HER2-negative breast cancer during postoperative adjuvant chemotherapy and their influencing factors. Materials and Methods. The medical records of patients with HER2-negative early breast cancer who visited Xuanwu Hospital from September 2018 to June 2021 were retrospectively analyzed. Demographic characteristics and baseline data of CEA and CA153 at initial diagnosis were collected. Data of CEA, CA153, biochemistry (including ALT, AST, rGT, triglycerides, cholesterol, and blood glucose) and blood routine (including white blood cells, neutrophils, monocytes, lymphocytes, and platelets) were also collected before chemotherapy, at the end of chemotherapy and more than 3 months after the end of chemotherapy. LY/MONO, NEUT/LY, PLT/LY, and systemic immune inflammation index (SII) were calculated and statistically analyzed using SPSSAU software. Results. A total of 90 patients were enrolled, all of whom were female, with a mean age of 55.11 ± 10.60 y. The value of CEA at initial diagnosis was 2.10 ± 1.11 ng/mL, and high expression was mostly correlated with past history of chronic diseases and tumor lymph node metastasis; the value of CA153 was 11.80 ± 6.60 U/mL, and high expression was correlated with high SII at initial diagnosis. Surgery did not affect the values of serum CEA and CA153. At the end of chemotherapy, CEA and CA153 were 2.68 ± 1.34 ng/mL and 18.51 ± 8.50 U/mL, respectively, which were significantly increased compared with those before chemotherapy, and were linearly correlated with the values before chemotherapy. They decreased (CEA 2.45 ± 1.19 ng/mL, CA153 10.87 ± 5.96 U/mL) again three months after the end of chemotherapy, manifested as “spiking” phenomenon, which was associated with lymph node metastasis at diagnosis, body metabolic disorders, and chronic inflammatory status. Conclusion. CEA and CA153 were increased presenting as “spiking” phenomena in patients with early HER2-negative breast cancer during postoperative adjuvant chemotherapy, and the peak of increase was linearly correlated with the indicators before chemotherapy. Clinical attention should be paid to this change to avoid excessive diagnosis and treatment leading to medical resource consumption.

show abstract

Utilization of aggregation‐induced emission materials in urinary system diseases

Xu,

Chen,

Wang

et al. 2024

Aggregate

View full text Add to dashboard Cite

With the development of aggregation‐induced emission (AIE) materials, the drawbacks of conventional fluorescence materials subjected to aggregation‐caused quenching (ACQ) have been resolved. This has allowed for the improvement of novel AIE fluorescent materials that exhibit enhanced photostability, a higher signal‐to‐noise ratio, and better imaging quality. Meanwhile, the enhanced phototherapeutic effect of AIE materials has garnered widespread attention in the realm of tumor treatment. The distinct physiological and anatomical characteristics of the urinary system make it suitable for the use of AIE materials. Additionally, AIE‐based phototherapy provides a superior solution to deal with the weaknesses of conventional treatments for urologic neoplasms. In this review, the scientific advancement on the use of AIE materials in urinary system diseases since the emergence of the AIE concept is reviewed in detail. The review highlights the promise of AIE materials for biomarkers detection, fluorescence imaging (FLI) in vivo and in vitro, AIE‐based phototherapy, and synergistic therapy from both diagnostic and therapeutic viewpoints. It is firmly believed that AIE materials hold immense untapped potential for the diagnosis and treatment of urologic disease, as well as all diseases of the human body.

show abstract

Evaluation of the safety and effectiveness of prostate‐specific antigen (PSA) monitoring in primary care after discharge from hospital‐based follow‐up following prostate cancer treatment

Cited by 3 publications

References 24 publications

The Influence of Tumor-Specific Markers in Breast Cancer on Other Blood Parameters

The Influence of Tumor-Specific Markers in Breast Cancer on Other Blood Parameters

Changes of Tumor Markers in Patients with Breast Cancer during Postoperative Adjuvant Chemotherapy

Utilization of aggregation‐induced emission materials in urinary system diseases

Contact Info

Product

Resources

About